# Aquestive Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Aquestive Therapeutics, Inc.). ## Overview Aquestive Therapeutics is a U.S.-based pharmaceutical company focused on developing and manufacturing medicines that use proprietary delivery technologies to make complex drugs easier to administer. Its core platform, PharmFilm®, supports oral film and other non-invasive dosage forms, while its pipeline includes Anaphylm™, a late-stage epinephrine prodrug candidate for severe allergic reactions, and the broader AdrenaVerse™ platform. The company also earns revenue from four licensed commercialized products that are marketed by partners in the U.S. and internationally, with Aquestive serving as the exclusive manufacturer. In addition to internal development, it collaborates with other pharmaceutical companies to bring new molecules to market using its delivery science and manufacturing capabilities. ## Products & services • Anaphylm™ epinephrine prodrug candidate for anaphylaxis • AdrenaVerse™ epinephrine prodrug pipeline platform • PharmFilm® oral film drug-delivery technology • Licensed commercial products manufactured for partners • Co-development and research services for pharma partners • License and royalty revenue from partnered products - **Proprietary product candidates** (15%) — Late-stage and pipeline medicines developed for Aquestive's own commercialization or partnering, including Anaphylm and AdrenaVerse. - **Manufacture and supply** (40%) — Contract manufacturing of licensed products that partners commercialize in the U.S. and globally. - **License and royalty revenue** (20%) — Royalties and licensing income from intellectual property and partnered products. - **Co-development and research services** (15%) — Development services and collaboration fees earned under pharmaceutical partner agreements. - **Commercialized proprietary products** (10%) — Self-commercialized products such as Libervant, where applicable, though access has been disrupted by litigation and FDA action. - Anaphylm™ epinephrine prodrug candidate for anaphylaxis - AdrenaVerse™ epinephrine prodrug pipeline platform - PharmFilm® oral film drug-delivery technology - Licensed commercial products manufactured for partners - Co-development and research services for pharma partners - License and royalty revenue from partnered products ## Customers Aquestive sells primarily to pharmaceutical partners rather than directly to end consumers, which makes its business model heavily B2B and collaboration-driven. Its manufacturing customers are licensees that rely on Aquestive to produce approved products to agreed specifications, while its licensing customers pay for access to proprietary delivery technology and intellectual property. The company also serves development partners that use its PharmFilm platform and related capabilities to advance new molecules through co-development arrangements. For its proprietary products, the end users are patients and prescribers, but commercialization depends on regulatory approval, market access, and distribution partners. - **Pharmaceutical licensees** (primary) — Buy manufactured doses of licensed products from Aquestive because the company is the exclusive manufacturer and they need reliable supply for commercialization. - **Development and collaboration partners** (secondary) — Use Aquestive's delivery technologies and development capabilities to advance new molecules and formulations through co-development agreements. - **Royalty and IP partners** (secondary) — Pay license and royalty fees tied to commercialized products that use Aquestive's intellectual property. - **Patients and healthcare providers** (emerging) — Use proprietary products such as Libervant and, if approved, Anaphylm, because the company aims to offer less invasive alternatives to standard care. - Pharmaceutical licensees that buy manufactured product supply - Partner companies that pay for access to PharmFilm and IP - Co-development collaborators seeking formulation and development support - Patients and prescribers using proprietary products such as Libervant or Anaphylm if approved - Commercial partners that market licensed products in the U.S. and abroad ## Geography Aquestive is headquartered in Warren, New Jersey, with manufacturing operations in Portage, Indiana, and its primary research laboratory also based in New Jersey. The company markets and supplies products through licensees in the United States and around the world, so its commercial footprint is global even though its own operating base is U.S.-centric. Regulatory oversight spans multiple jurisdictions, including the FDA in the U.S. and inspections by TGA, DEA, ANVISA, and EMA, which matters because manufacturing and quality compliance are central to its supply business. The company does not disclose a country-level revenue split in the provided excerpts, so the geographic profile is best understood through its U.S. operating base and international partner commercialization. - Headquarters and primary R&D are in Warren, New Jersey - Manufacturing is centered in Portage, Indiana - Licensed products are marketed by partners in the U.S. and internationally - Facilities are subject to FDA, TGA, DEA, ANVISA, and EMA oversight - No country-level revenue split was disclosed in the excerpts ## Strategy Aquestive's strategy centers on advancing Anaphylm and the AdrenaVerse platform while preserving optionality through partnering and outlicensing. The company is also focused on supporting its existing licensed-product manufacturing base, which provides commercial revenue and helps fund development activities. Management has signaled that liquidity is a major constraint, so cost control, external financing, and potential strategic transactions are part of the operating plan. The company is trying to balance near-term cash preservation with continued investment in late-stage development programs that could create a larger proprietary commercial opportunity. - **Advance Anaphylm through regulatory approval** (short-term) — Anaphylm is the company's most important late-stage proprietary asset and could materially change the business mix if approved. - **Preserve liquidity and access external capital** (short-term) — The company expects continued losses and negative cash flow, so funding is required to sustain development and debt service. - **Monetize assets through partnering or outlicensing** (medium-term) — Outlicensing can reduce commercialization burden and create milestone or royalty income while limiting cash burn. - **Expand the proprietary delivery platform** (medium-term) — PharmFilm and related technologies are the company's core differentiation and can support future collaborations. - Advance Anaphylm through FDA review and toward commercialization - Develop the AdrenaVerse epinephrine prodrug platform as a pipeline base - Use outlicensing or strategic transactions to monetize assets if needed - Support licensed-product manufacturing to generate recurring revenue - Control costs and preserve liquidity while funding clinical development - Maintain optionality between self-commercialization and partnering ## Risks Aquestive faces substantial development and regulatory risk because its lead proprietary programs depend on FDA approval and the company has already received a complete response letter for Anaphylm. Its business is also exposed to clinical execution risk because it relies heavily on third-party CROs, investigators, and consultants to run trials and generate the data needed for approval. Commercial risk is elevated because the company depends on a small number of licensed products and on partner commercialization decisions, while litigation or loss of market access can quickly disrupt revenue, as seen with Libervant. More broadly, the company operates in a highly competitive pharmaceutical market with strong intellectual property defense, pricing pressure, reimbursement uncertainty, and ongoing need for capital, all of which can affect both growth and survival. - **FDA regulatory setbacks for Anaphylm** [high] — The lead proprietary program depends on resolving FDA concerns and obtaining approval, and a delay or rejection would materially impair growth prospects. - **Liquidity shortfall and refinancing risk** [critical] — The company expects continued losses and needs capital to fund operations, development, and debt service. - **Clinical trial execution dependence on CROs** [high] — Delays, data quality issues, or vendor failures could slow or invalidate development programs. - **Commercial concentration in a limited product set** [high] — Revenue depends on a small number of licensed products and proprietary launches, making the business vulnerable to single-product disruption. - **Intellectual property and litigation exposure** [medium] — The company relies on proprietary delivery technologies and may face disputes over patents, trade secrets, or commercialization rights. - FDA approval risk for Anaphylm and other pipeline assets - Dependence on third-party CROs for clinical trial execution - Liquidity risk and need for external financing - Litigation and market-access risk, including product interruptions - Intellectual property protection and trade secret disputes - Competition from larger pharma and alternative delivery technologies - Manufacturing and regulatory compliance risk across multiple agencies ## Accounting Revenue recognition is a key accounting issue because Aquestive earns revenue from manufacturing, licensing, royalties, development services, and proprietary product sales, each of which can follow different recognition patterns. Proprietary product revenue is recognized when product ships and title passes, but the company records variable consideration estimates for returns, discounts, rebates, and co-pay support, which can materially affect quarterly results. The sale of future revenue related to KYNMOBI is accounted for as debt financing, so interest expense and the carrying value of the liability depend on estimates of future royalty streams. Because the company is a smaller reporting company with ongoing losses, investors should also watch for judgment in accruals, contingent liabilities, and any impairment or valuation issues tied to development assets and commercialization assumptions. - **Revenue recognition across multiple revenue streams** — Affects reported revenue mix and comparability - **Variable consideration reserves** — Affects net revenue and accrued liabilities - **Sale of future revenue liability accounting** — Affects leverage presentation and interest expense - **Development-stage asset valuation** — Affects asset carrying values and loss recognition - Point-in-time revenue recognition for proprietary product shipments - Variable consideration estimates for returns, rebates, and discounts - Royalty and license revenue timing tied to partner sales and contract terms - Sale of future revenue accounted for as debt financing - Quarterly reassessment of allowances and accrued liabilities - Potential impairment or valuation judgments for development assets --- *Last updated: 2026-08-11T04:46:21.207803+00:00*